Citius Pharmaceuticals reports first revenue of $3.9 mln

Overview

• Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026

• Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38

• Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025

Outlook

• Citius anticipates growth from international market expansion and oncology franchise development

• Company plans to expand LYMPHIR access in Europe and the Middle East

• Citius focuses on technology-driven platform to enhance market penetration

Result Drivers

• LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025

• AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration

• INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79

• The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nPn7wjdcta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.